Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2017

  • ID: 4399904
  • Clinical Trials
  • Region: Global
  • 570 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Mallinckrodt Plc
  • Neopharm Ltd
  • Novartis AG
  • MORE
Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2017" provides an overview of Graft Versus Host Disease (GVHD) clinical trials scenario. This report provides top line data relating to the clinical trials on Graft Versus Host Disease (GVHD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Mallinckrodt Plc
  • Neopharm Ltd
  • Novartis AG
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Graft Versus Host Disease (GVHD)
Aug 14, 2017: Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease
Jul 25, 2017: Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
Jul 20, 2017: Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease
Jul 11, 2017: Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
Jul 05, 2017: FDA Meeting Provides Clear Path for Cynata US Development Plans
Jun 26, 2017: Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy
Jun 24, 2017: European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids
Jun 23, 2017: Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease at R&D Day
Jun 14, 2017: Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Source

List of Tables
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Region, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, North America, Top Countries, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017*
Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, G7 Countries (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, E7 Countries (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Phase, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Graft Versus Host Disease (GVHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Region (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017*
Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, G7 Countries (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, E7 Countries (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Graft Versus Host Disease (GVHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Ltd
  • Mallinckrodt Plc
  • Pfizer Inc
  • Neopharm Ltd
  • Bellicum Pharmaceuticals Inc
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll